Literature DB >> 22341751

[Aspergillosis. Clinical forms and treatment].

Jesús Fortún1, Yolanda Meije, Gema Fresco, Santiago Moreno.   

Abstract

Invasive aspergillosis, chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis are the clinical forms of aspergillosis. Although there is a great number of Aspergillus species, Aspergillus fumigatus-complex is the more frequent aetiological agent, regardless of clinical form or baseline condition. The increase in immunosuppressive agents and the higher use of corticosteroids in chronic obstructive pulmonary disease have led to aspergillosis becoming more prominent in recent years. Galactomannan detection and radiological diagnostic images complement the limitations of microbiology cultures in these patients. Voriconazole and liposomal amphotericin B are the gold standard in patients requiring therapy, and posaconazole, itraconazole, caspofungin and other echinocandins are effective alternatives. The prognosis depends of clinical forms and characteristics of the host, but it is particularly poor in the disseminated invasive forms.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341751     DOI: 10.1016/j.eimc.2011.12.005

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  2 in total

1.  A 9-Year Experience of Aspergillus Infections from Isfahan, Iran.

Authors:  Mostafa Chadeganipour; Rasoul Mohammadi
Journal:  Infect Drug Resist       Date:  2020-07-14       Impact factor: 4.003

2.  Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.

Authors:  Alicia López-Sánchez; Alba Pérez-Cantero; Carlos Torrado-Salmerón; Adela Martin-Vicente; Víctor García-Herrero; María Ángeles González-Nicolás; Alberto Lázaro; Alberto Tejedor; Santiago Torrado-Santiago; Juan José García-Rodríguez; Javier Capilla; Susana Torrado
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.